Further, RORα inhibitor, SR1001, presented a therapeutic effect in hypoxia-induced pulmonary hypertension (45), and the expression of RORα was upregulated after CS exposure as well as in patients with COPD/emphysema compared with healthy controls (46). Here, RORA is linked to pulmonary emphysema.